LabConnect Executive and Leadership Team

Richard Harris, the Chief Executive Officer at LabConnect, directs the overarching corporate strategy and long-term vision for global central laboratory operations. Harris architects the expansion of service offerings to support biopharmaceutical clients through every stage of clinical development, from preclinical research to Phase IV trials. By aligning internal scientific capabilities with the evolving needs of the drug development industry, the Chief Executive Officer ensures that the organization maintains a competitive edge in major and emerging markets. This leadership role involves fostering partnerships with CROs and pharmaceutical firms to streamline complex logistics and sample management. Richard Harris drives the integration of state-of-the-art technology across all laboratory functions to improve data accuracy and study efficiency. Through rigorous oversight of organizational performance, the Chief Executive Officer secures the company's position as a preeminent provider of scientific functional outsourcing and clinical support services.

Mitch Blumenfeld, the Chief Financial Officer at LabConnect, manages the fiscal health and capital allocation strategies required to sustain global laboratory infrastructure. Blumenfeld oversees the financial planning and analysis functions, ensuring that investments in world-class laboratory facilities and advanced tracking technologies align with corporate growth objectives. By monitoring revenue streams from diverse clinical study portfolios, the Chief Financial Officer optimizes resource distribution to support high-volume routine testing and complex sample management projects. This role involves collaborating with executive leadership to evaluate market opportunities and mitigate financial risks associated with international expansion. Mitch Blumenfeld drives the development of robust financial reporting systems that provide transparency for stakeholders and support long-term sustainability. Through disciplined management of the company's financial assets, the Chief Financial Officer enables the organization to deliver consistent, high-quality support services to biopharmaceutical clients worldwide.

Michael Lalor, the Interim Chief Financial Officer & Vice President, Finance at LabConnect, executes the daily financial operations and accounting functions that support the company's clinical service delivery. Lalor manages the budgeting processes and internal controls, ensuring that financial workflows remain efficient during periods of organizational scaling. By overseeing the financial aspects of scientific functional outsourcing, the Interim Chief Financial Officer & Vice President, Finance maintains the fiscal stability required for routine testing and complex study management. This role involves providing detailed financial insights to the executive team to facilitate informed decision-making regarding operational expenditures and project-based resource allocation. Michael Lalor drives the refinement of financial processes to improve accuracy in cost tracking and billing for global biopharmaceutical clients. Through meticulous attention to financial detail, the Interim Chief Financial Officer & Vice President, Finance supports the overall mission of providing reliable, high-quality laboratory support services.

Richard (Rich) LaBarca, the Chief Technology Officer at LabConnect, architects the digital infrastructure and data management platforms that connect high-quality samples to accurate clinical data. LaBarca directs the implementation of innovative software solutions designed to streamline kit building, sample tracking, and biorepository management for complex studies. By integrating advanced technology into the laboratory workflow, the Chief Technology Officer enhances the precision and reliability of data delivered to biopharmaceutical and CRO clients. This leadership role involves overseeing the cybersecurity and data integrity protocols necessary to protect sensitive clinical information across global operations. Richard (Rich) LaBarca drives the continuous improvement of proprietary systems to meet the unique, customized needs of diverse clinical trials. Through the deployment of scalable technological frameworks, the Chief Technology Officer ensures that the company remains at the forefront of digital transformation within the clinical research and development sector.